Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native in...
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT02027935
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT01993719
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT01967823
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients with Stage III-IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT01955460
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT01814046
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT01754376
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT01740557
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- St. Anna Kinderkrebsforschung
- Target Recruit Count
- 3300
- Registration Number
- NCT01704716
- Locations
- 🇵🇱
Medical University in Gdansk, Gdansk, Poland
🇵🇱Children's University Hospital in Lublin, Lublin, Poland
🇵🇱University of Medical Sciences Poznan, Poznan, Poland
Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- St. Anna Kinderkrebsforschung
- Target Recruit Count
- 288
- Registration Number
- NCT01701479
- Locations
- 🇪🇸
Hospital Universitario La Fe, Valencia, Spain
🇮🇹Gaslini Children's Hospital, Genova, Italy
🇫🇷Institut Gustave Roussy, Villejuif, France
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01697527
- Locations
- 🇺🇸
University of California at Los Angeles (UCLA ), Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.